NASDAQ:CMPX

Compass Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CMPX

*Your capital is at risk

$2.10

+0.0200 (+0.96%)

At Close: Jun 03, 2026

Compass Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -32.19. In total, the insiders bought 16.48M and sold 14.61M CMPX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-32.19
● Buy	16.48M shares
● Sell	14.61M shares
89% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Jan 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -32.19. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (89% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 27, 2025 Buy	Common Stock P-Purchase	Schuetz Thomas J. Chief Executive Officer	CEO / President	10 000 Value: $21.1K
May 27, 2025 Buy	Common Stock P-Purchase	Schuetz Thomas J. Chief Executive Officer	CEO / President	10 000 Value: $21.1K
Apr 09, 2025 Sell	Common Stock S-Sale	Gordon Carl L	Director	3 571 428 Value: $5.68M
Apr 09, 2025 Sell	Common Stock S-Sale	Orbimed Advisors Llc	Director	3 571 428 Value: $5.68M
Apr 09, 2025 Sell	Common Stock S-Sale	Orbimed Advisors Llc	Director	3 571 428 Value: $5.68M
Apr 09, 2025 Sell	Common Stock S-Sale	Gordon Carl L	Director	3 571 428 Value: $5.68M
Apr 07, 2025 Buy	Common Stock P-Purchase	Anderman Jonathan Gen Counsel & Corporate Sec	Officer	20 000 Value: $30.8K
Apr 07, 2025 Buy	Common Stock P-Purchase	Lerner Neil Chief Accounting Officer	Officer	20 000 Value: $28.4K
Apr 07, 2025 Buy	Common Stock P-Purchase	Lerner Neil Chief Accounting Officer	Officer	20 000 Value: $28.4K
Apr 07, 2025 Buy	Common Stock P-Purchase	Anderman Jonathan Gen Counsel & Corporate Sec	Officer	20 000 Value: $30.8K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Shin Barry CFO	C-Suite Officer	250 000 Value: $912.5K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Schuetz Thomas J. Chief Executive Officer	CEO / President	1 500 000 Value: $5.48M
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Lindahl Richard S Director	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Lerner Neil SVP, Cao	Officer	200 000 Value: $730.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Gray Mary Ann Director	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferneau Philip Director	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Chiniara Ellen Director	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Anderman Jonathan Sr Vp, Gen Counsel & Corp Sec	Officer	280 000 Value: $1.02M
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Gordon Carl L	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Boylan James P Director	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Boylan James P Director	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Gordon Carl L	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Anderman Jonathan Sr Vp, Gen Counsel & Corp Sec	Officer	280 000 Value: $1.02M
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Chiniara Ellen Director	Director	40 000 Value: $146.0K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferneau Philip Director	Director	40 000 Value: $146.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COMPASS THERAPEUTICS, INC.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that i...

Read Full Profile Here